Gr8, I didn't get all my Qs answered but nice to see lots more Qs from other investors, many of which did colour in some of mine..
Considering I invested in AT1 with a long view of $5 SP over 5yrs+ (and hopefully higher over the next 10yrs+), I am still comfortable to hold as the company is continuing steady progress.
As we have discussed previously, since today's presentation covers data from last Qtrly, we already understood the $ and ann's associated with it...so no major past news...but interesting to see CY21 plans + potential
What I did like hearing (for the continued long term SP value, device sales and rev growth) was:
- Divoc and India geo is still in play..yay! AT1 planning to provide the US FDA approved test version, which will be accepted by ICMR (India approval body as per their rules). Ag test is already approved in USA (so the India version will be sole AT1 branded) + the Ab test is pending expanded approval (again this will be sole AT1 branded)
- USA geo has several short-long plays (expanded approval for co-branded Covid19 Ab test which has 2 tiers of rev potential + FebriDx OEM approval in 2HFY21)
- AU geo, good to find out that the 400k Covid19 rev (Ab+Ag?) seems to have come from the AU-China travel market. Travel, in all its various channels/borders is far larger demand + more lucrative than the AU gov hotel quarantine/public testing market (which comes with the baggage of reluctant gov takeup + limited qty in our low infection geo). Increased success from vaccines should also assist in this space, since these will require some form of immunity validation testing over time VS the un-vaccinated traveller market will still exist for 1-2yrs+, globally, due to vaccine availability timeline.
- Covid19 long term market + post-vaccine testing...I knew of the medical community news stories Covid19 morphing into an endemic disease, but hadn't considered this a a steady rev channel for AT1's Ag/Ab tests..and future versions dedicated for post-vaccine tests over 5-10yrs. I prefer steady long term test earners more than just short term burn-forget trends....but nice to get both, which 2021-22 still seems to have this potential via above pending geos.
- still parallel focus on bringing out 2 new commercialised products + the digital health/app space...so not dropping the ball from expanding the toolkit + chance of different market partners for the next 3-5yrs, especially in the digital space, which can be again lucrative in developed countries.
Still on the edge of cashflow positive, still ramping up 2021 production plans, still have future tests in play (HCV, Malaria self-test etc)...still seems good for my long term return.
- Don't know if they are still applying/planning to apply for Covid19 tests in SEAsia geos (previously ann'd; will email this Q)
- Don't know if they are planning Ag test launch in EU geo (with/without Access Bio; will email this Q)
Expand
